Delaying emergence of resistance to KRAS inhibitors with adaptive therapy: “treatment-to-contain” instead of “treatment-to-cure”
KRAS mutations are among the most common oncogenic abnormalities in cancer. Until recently, drug discovery pursuing KRAS did not produce therapeutic benefits for patients. Specific KRAS inhibitors, such as sotorasib and adagrasib, which bind covalently to codon 12 of substituted glycine to cysteine...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Published: |
Tech Science Press
2022
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/100887/ https://www.techscience.com/oncologie/v24n2/48748 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!